The immunological consequences of cryoablation for gliomas are largely unknown. cryoablation is an attractive therapeutic option for tumors due to its minimally invasive nature. cryoablation is also potentially immunogenic. With an aim to explore changes in cellullar immunity following argon-helium cryosurgery, we established Wistar rat models bearing subcutaneous C6 glioma and divided the rats into the normal control (30 rats), sham-operated (33 rats), surgical resection (30 rats), and cryosurgery (33 rats) groups with corresponding treatments. The tumor cell morphology was observed, and changes in the T lymphocyte subset and NK lymphocyte subset and the ratio of Th1/Th2 were assessed with flow cytometry following the cryosurgery. The results showed that subcutaneous tumor implantation was successful in all cases and this was confirmed histologically. Compared with surgical resection that caused significant reduction in CD3 + , CD4 + , CD14 + , CD16+56 cell percentages, cryosurgery resulted in significantly increased percentages of CD3 + , CD4 + , CD14 + , CD16+56 cells (P < 0.05) with a increase of the Th1/Th2 ratio 7 days after the operation.
Introduction
A new technique that allows targeted local cryoablation of solid tumors, argonhelium cryosurgery, induces rapid freeze-thawing of the tumor tissue by producing an ultralow temperature in tumor foci and results in total destruction of tumor cells. Encouraging results of cryosurgery have been reported in the treatment of solid tumors (1) (2) (3) (4) (5) . Nevertheless, the cellular immunity effects of cryotherapy of any solid tumor are contreversial, unknown or mixed. When used in the treatment of gliomas, remain preliminary (6) . In this study, we performed argon-helium cryosurgery in Wistar rat models bearing C6 gliomas, and observed changes in cellular immunity. By evaluating the postoperative changes in T cell subsets, NK cell subsets and the ratio of Th1/Th2 in the rats, we aimed to explore the effects of argon-helium cryosurgery on the cellular immunity and provide experimental evidence for the clinical application of this technique in glioma treatment.
Materials and Methods

Animals, Reagents and Equipment
A total of 126 inbred Wistar rats (75 males and 75 females, 10-12 weeks old) weighing 180-220 g were provided by the Laboratory Animal Center of Southern Technology in Cancer Research & Treatment, Volume 10, Number 1, February 2011 Medical University (Certificate No.SCXKyu2006-0015) . C6 rat glioma cell line was maintained in our institute. RPMI 1640 medium, 0.25% trypsin, and fetal bovine serum (FBS) used were products of Hyclone Co (USA). The kit for HE staining was provided by the IBL Co (Germany). The TUNEL assay kit was supplied by Boster Biological Technology Ltd (China). Mouse anti-rat CD3 + , CD4 + , CD8 + , CD14 + , CD16+56 antibodies were purchased from Becton Dickinson (BD, USA). A flow cytometer (BD, USA), and Cryocare surgical system (Endocare, USA) were used in this study.
Animal Model Establishment
The C6 glioma cells were cultured in RPMI 1640 medium supplemented with FBS at 37ºC in the presence of 5% CO 2 in a humidified incubator. The culture medium and FBS were changed every 24 h, and cell growth was examined daily under a phase-contrast microscope and photographed. When reaching 80%-90% confluence, the cells were washed with D-Hanks solution and digested with 0.25% trypsin for 4 minutes, followed by addition of FBS to terminate the digestion. The cells were suspended in serum-free RPMI 1640 medium and harvested by centrifugation at 800r/min for 8 min. The cells were then suspended in 0.01 Mmol/L phosphate buffer solution (PBS, Ph = 7.4) at the density of 1 × 10 10 to 5 × 10 10 /ml. Under sterile conditions, 0.5 ml of the cell suspension was slowly injected into the subcutaneous tissue on the back of the rats, with the needle remaining inserted for 3 min before withdrawal. The tumor growth was observed every other day, and the maximum tumor diameter and width were measured.
Animal Grouping and Treatment
When the diameter of tumors reached nearly 2.5 cm on day 20 following tumor cell inoculation, the rats were randomized into 4 groups, namely the normal control group (30 rats), sham-operated group (33 rats), surgical resection group (30 rats), and cryosurgical group (33 rats). The rats in the normal control group received no particular interventions. For cryosurgical ablation of the tumors, the rats were anesthetized with 3.6% chloral hydrate and a 3.5-cm-long incision was made 0.5 cm from the subcutaneous tumor to expose the tumor. A 2-mm cryoprobe was inserted into the center of tumor mass for a 2-min cryoablation at -140ºC by means of the double cycle freezing and subsequent rewarming to 0ºC for another 2 min before cryoprobe withdrawal. In the surgical resection group, the tumor was exposed and completely resected without cryoablation. In the sham-operated group, the cryoprobe was inserted into the tumor mass and maintained for 4 min without initiating cryablation. All the operations were performed under strictly sterile conditions. After the operations, the incision was routinely closed and the rats were kept in normal housing conditions.
Observation of Tumor Cell Morphology
For morphological observation of the tumor cells, 3 rats from the sham-operated and cryosurgical groups were sacrificed 48 h after the operations, and the tumors were carefully removed and fixed in formaldehyde to prepare routine frozen sections, which were observed under light microscope with HE staining.
T lymphocyte Cell Subset Analysis
In each of the groups, 0.25 ml anticoagulated venous whole blood was obtained from the rats 24 h before the operations and then at 7 days and 14 days after the operations. Fluorescence labeled CD3 + , CD4 + , CD8 + , CD14 + , CD16+56 monoclonal antibody was added into the test tubes containing 50 μl blood samples, and after gentle shaking, the tubes were placed at room temperature for 15 min, followed by the addition of 500 μl hemolysin. The tubes were stored in darkness at room temperature for 15 min and centrifuged at 5000 r/min for 5 min. After depletion of the supernatant, 500 μl PBS was added into the tubes and mixed by gentle shaking of the tubes for 10 min. Flow cytometry was performed to determine the percentages of CD3 + , CD4 + , CD8 + , CD14 + , CD16+56 cell subsets in the peripheral blood using a FACS calibur flow cytometer.
Flow Cytometry for Cytokine Profile Analysis
At varying time points after either cryoablation or surgery, splenocytes were removed aseptically. Spleen cells obtained from rats were prepared with 2 × 10 6 /ml. Con A (5 μg/ml) with monensin in proper dose were added into the cell suspensions. The cells were then incubated for 8 hours at 4ºC. After gentle shaking, the tubes were placed at room temperature for 10 min, followed by addition of 2 ml hemolysin. The tubes were stored in darkness at room temperature for 15 min and centrifuged at 5000 r/min for 15 minutes. The supernatants were washed twice with 2 ml permeabilization Wash buffer and centrifuged at 5000 r/min for 15 minutes. Fluorescence labeled IFN-γ and IL-4 monoclonal antibody was added into the test tubes in which were stored in darkness at room temperature for 30 minutes. The cells were then washed twice. Flow cytometry was performed to determine the percentages of IFN-γ, IL-4 cell subsets using a FACS Calibur flow cytometer.
Statistical Analysis
The data were presented as Mean ± SD. The differences between different time points and between the groups were analyzed with repeated measurement analysis of variance using SPSS13.0 software. A P value less than 0.05 was considered to indicate a significant difference.
Results
Tumor Volume Examination of the Animal Models
After C6 cell inoculation, the volume of the tumor mass increased gradually, and as of the 20 th day after the inoculation, the diameters of the tumor masses had reached 2.0-3.0 cm, but none of the rats died due to the tumor growth. In the cryosurgery group, the tumor volume tended to gradually decrease after the operation.
HE Staining Detection
HE staining showed tumor cell rupture, nuclear condensation and coagulative necrosis of the C6 glioma following cryoablation. One week after the cryablation, obvious congestion and bleeding occurred with formation of granulation tissues on the margin of the ablated area ( Figure 2 ).
T lymphocyte Subset Changes
Compared with the preoperative levels, the percentages of CD3 + , CD4 + , CD14 + , CD16+56 cells in the surgical resection group decreased significantly 7 days after the operation followed by a gradual increase, but recovered the preoperative level at 14 days after the operation (P < 0.05). In the cryosurgery group, the CD3 + , CD4 + , CD14 + , CD16+56 cells were found to have obviously increased on days 7 and 14 after the operation, showing significant differences from those in the other 3 groups (P < 0.05). The CD3 + , CD4 + , CD14 + , CD16+56 cells showed no significant differences cell percentages between the normal control and sham-operated groups at 7 and 14 days after the operation. In all 4 groups, CD8 + cells increased with time after the operation, but no significant differences were found between the 4 groups at each of the time points for which measurements were taken (P < 0.001) (Figure 3 ).
Th1 Cytokine IFN-g Positive Cells /Th2 Cytokine IL-4 Positive Cells Analysis
Compared with the preoperative levels, the percentages of IFN-γ positive cells in the surgical resection group decreased significantly 7 days after the operation followed by gradual increase, but recovered the preoperative level by the 14 th day after the operation (P < 0.05). In the cryosurgery group, the IFN-γ positive cells were found to have obviously increased on days 7 and 14 after the operation, showing significant differences from those in the other 3 groups (P < 0.05). The IFN-γ positive cells showed no significant differences between the normal control and sham-operated groups at 7 and 14 days after the operation. In all the 4 groups, IL-4 positive cells increased with time after the operation, but no significant differences were found between the 4 groups at each of the time points for which measurements were taken (Figure 4 ). immunity was observed in the control and sham-operated groups.
By producing ultralow temperatures in the tumor foci for rapid freeze-thawing of the tumor tissues, argon-helium cryosurgery causes cell membrane damage and tissue
Discussion
In our study, these results demonstrate that in addition to tumor cell destruction, cryosurgery also results in enhanced cellular immunity of the C6 glioma-bearing rats (P < 0.05). However no cell morphology and cellular Argon-helium cryosurgery has shown encouraging therapeutic effects on gliomas, Nevertheless, the application of this technique in the treatment of gliomas still remains preliminary, and reports of only a handful cases were available to demonstrate its good therapeutic effect in the management of gliomas (10, 11, 12) without support by sufficient laboratory evidences in our study, we aim to detect the changes of cellular immunity and to proof the cellular immunity by cryosurgery with more data. The comparison of the tumor histopathology and cellular immunity between the rats receiving surgical resection and cryosurgery demonstrated that argon-helium cryosurgery could effectively reduce the tumor load, induce tumor cell apoptosis and necrosis, and enhance the antitumor immunity. One week after the cryosurgery, the percentages of CD3 + and CD4 + cells increased obviously and the T cell-mediated immune response was significantly enhanced in comparison with those in rats with surgical tumor resection, and such changes was even more obvious at two weeks after the operation. Cryosurgery also resulted in increased CD8 + cell percentage, but this increment was not statistically significant in comparison with that in the other groups. The increased percentage of the CD4 + T helper cells and relatively stable percentage of CD8 + suppressor T cells following cryosurgery led to increased CD4 + /CD8 + cell ratio, suggesting an enhancement in host antitumor immunity by cryosurgery. As we all know, Macrophages play important roles in antitumor immunity, and can kill tumor cells in multiple ways. NK cells can kill tumor cells directly. We detected the immunological markers CD14+, CD16+56 for macrophages and NK respectively, showing their significant increase when compared to the other group. In view of the increase of CD3+, CD4+ T cells, degeneration and necrosis in the tumors. This technique allows precise cryoablation of a wide variety of neoplasms, and has been used in the clinical treatment of cancers in the liver, lung, pancreas, prostate and breast, etc. Staren et al (7) found that in rats bearing orthotopically transplanted breast carcinoma, cryosurgery caused significant destruction of the tumor tissue and obviously prolonged the survival of the rats. They also noted the importance of achieving a tissue temperature of -40°C or colder and the enhanced destructive effect of prolonged freezing and repetition of the freeze-thaw cycles. Rabin et al (8) and Otterson et al (9) demonstrated similar effects of cryosurgery in sheep and goat breasts. Sabel et al (10) reported that in BALB/c mice bearing MT-901 tumors, cryoablation induced a tumorspecific T-cell response in the tumor-draining lymph nodes (TDLN) including significantly increased interleukin-12 (IL-12) and interferon-c (IFN-c) levels, with enhanced systemic natural killer (NK) cell activity, which were associated with rejection of tumors upon re-challenge. Hamad et al (11) performed argon-helium cryosurgery in 32 cases of hepatocellular carcinoma, and found that these patients had prolonged postoperative survival and improved biochemical, hematologic, and immunologic indices as compared with the control group. Similar results were also reported in the treatment of prostate and lung cancers. All these data suggest that argon-helium cryosurgery causes not only tumor tissue destructions but also enhancement of the host immune function through several possible mechanisms.
The brain glioma patients that fail to respond to or are ineligible for chemotherapy or radiotherapy often present difficult clinical cases, for which cryosurgery provides a valuable therapeutic option. Zhang et al (12) attempted stereotactically guided argon-helium cryosurgery in 12 glioma cases, and achieved obviously prolonged survival of the patients. Several of the patients survived for over 5 years after the operation without glioma recurrence, demonstrating an effect significantly better than surgical resection, radiotherapy and we tested cytokine expression for Th1/Th2; IFN-γ levels were raised obviously, IL-4 had shown significant change; indicating that Th1 activity began to exceed that of Th2, indicating that cellular immune functions were enhanced.
Recent studies suggest that several factors contribute to the enhancement of the host cellular immunity following cryosurgery (11, 12, 13) . The necrotic tumor tissue as a result of cryosurgery is associated with better tumor-specific antigen exposure and promotes the release of the soluble tumor antigens to active antigen presenting action resulting in the stimulation of the T cells and NK cells, causing the percentage of CD3+, CD4+, CD14+, CD16+56 to increase. This is probably the most important reason for the enhanced host immunity after cryosurgery. Also of great importance is the reduced release of immunosuppressive factors from the tumor cells after tumor cell destruction by cryosurgery, which relieves the host of immune suppression imposed by the tumors. In addition, cryosurgery causes minimal traumatic injury and may avoid the need for or reduce the dose of postoperative radiotherapy and chemotherapy, therefore allowing protection of the host immune system from damage by radiotherapy and chemotherapy. This finding sheds light on cellular immunity against gliomas when using cryosurgery as a treatment. However, this approach has to be thoroughly evaluated with regard to its mechanism, immunologic therapeutic effects and time required for, and persistence of immunologic killing.
